Tchaikapharma High Quality Medicines AD Logo

Tchaikapharma High Quality Medicines AD

Develops and makes affordable generic drugs for cardiovascular & metabolic diseases.

THQM | BSOBGN

Overview

Corporate Details

ISIN(s):
BG1100008074
LEI:
5299003VDHTK75D1JE38
Country:
Bulgaria
Address:
бул./ул. бул. Г.М.ДИМИТРОВ № 1, 1172 София
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tchaikapharma High Quality Medicines AD is a pharmaceutical company focused on the development and manufacturing of affordable, high-quality generic and in-licensed medicines. The company's core expertise lies in producing cost-effective therapies for socially significant diseases. Its product portfolio covers several therapeutic areas, including cardiovascular, cerebrovascular, metabolic, and anti-inflammatory conditions. Tchaikapharma specializes in complex generics (polypills), aiming to improve treatment outcomes and increase patient access to modern healthcare solutions for both individuals and healthcare professionals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-04-15 23:00
Annual / Quarterly Financial Statement
5299003VDHTK75D1JE38-20231231-BG-CON_CALCULATION-RES.html
English 47.8 KB
2024-04-15 23:00
Annual / Quarterly Financial Statement
609557-7TH_2023 CONS_BG_signed.xls
Bulgarian 719.5 KB
2024-04-15 23:00
Annual / Quarterly Financial Statement
609559-7TH_2023 CONS_EN_signed.xls
Bulgarian 235.0 KB
2024-04-15 23:00
Annual Report (ESEF)
609558-5299003VDHTK75D1JE38-20231231-EN-CON.zip
Bulgarian 6.4 MB
2024-03-26 23:00
Interim Report
608037-SPRAVKA_1_IND_GFO_6M.xls
Bulgarian 722.0 KB
2024-03-26 23:00
Management Discussion and Analysis
5299003VDHTK75D1JE38-20231231-BG-SEP.xhtml
Bulgarian 21.8 MB
2023-07-12 23:00
Regulatory News Service
7TH_2022 CONS_BG.xls
Bulgarian 718.0 KB
2023-06-07 23:00
Interim Report
SPRAVKA_1_IND_GFO_6M_signed.xls
Bulgarian 778.5 KB
2023-06-07 23:00
Annual Report
5299003VDHTK75D1JE38-20221231-BG-SEP.xhtml
Bulgarian 37.0 MB
2022-07-26 23:00
Annual / Quarterly Financial Statement
5299003VDHTK75D1JE38-20211231-BG-SEP.xhtml
Bulgarian 5.7 MB
2022-07-26 23:00
Annual / Quarterly Financial Statement
7TH_2021_signed.xls
Bulgarian 939.0 KB
2022-07-26 23:00
Annual Report (ESEF)
5299003VDHTK75D1JE38-20211231-BG-CON.zip
Bulgarian 3.2 MB
2022-07-26 23:00
Annual / Quarterly Financial Statement
7TH_2021 CONS.xls
Bulgarian 900.0 KB

Automate Your Workflow. Get a real-time feed of all Tchaikapharma High Quality Medicines AD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tchaikapharma High Quality Medicines AD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tchaikapharma High Quality Medicines AD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece MEDIC
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea 054180
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan 2207

Talk to a Data Expert

Have a question? We'll get back to you promptly.